Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
By M. Takawa, K. Masuda, M. Kunizaki, Y. Daigo, K. Takagi, Yukiko Iwai, Hyun-soo Cho, G. Toyokawa, Y. Yamane, Kazuhiro Maejima and 9 more. 2011
190 citations recorded by the source corpus.
Subfields: Molecular Biology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Ryuji Hamamoto
- Yusuke Nakamura
- N. Dohmae
- Takehiro Suzuki
- Makoto Nakakido
- G. Toyokawa
- Lianhua Piao
- S. Hayami
Citations in the corpus
- Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN (2015, methodology): “siEnhanced green fluorescent protein and siNegative control (siNC), which is a mixture of three different oligonucleotide duplexes, were used as control siRNAs [25–28].”
- Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. (2011, background): “[28] Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, et al.”
- RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. (2012, background): “We previously showed that some histone methyltransferases (HMTs) play vital roles in human cancer pathogenesis [22,34–36].”
- The JmjC domain‐containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene (2012, methodology): “Immunohistochemical staining and tissue microarray Immunohistochemical analysis was performed using a specific polyclonal rabbit-KDM3A antibody (12835-1-AP, Proteintech Group, Chicago, IL) as described previously.(35,36) For clinical bladder and lung cancer tissue microarray, En Vision kit horseradi”
- Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer (2017, unknown): “EZH2 has been shown to be frequently overexpressed in various types of tumors, and a higher level of EZH2 might be associated with poor prognosis [22].”
- Late Cornified Envelope Group I, a Novel Target of p53, Regulates PRMT5 Activity (2014, background): “Current progress of molecular medicine revealed that the enzymes relevant to histonemethylation play critical roles in human carcinogenesis [28,35–45].”
- Metabolic reprogramming and epigenetic modifications on the path to cancer (2021, background): “…poor clinical outcomes of patients with lymphoma and solid tumors, including prostate, breast, kidney, and lung cancers (Varambally et al., 2002; Moss and Wallrath, 2007; Yu et al., 2007; Varambally et al., 2008; Wagener et al., 2010; Takawa et al., 2011; McCabe et al., 2012; Volkel et al., 2015).”